<DOC>
	<DOCNO>NCT01084083</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation therapy use high energy x-ray kill tumor cell . Giving paclitaxel , cisplatin , cetuximab together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study paclitaxel , cisplatin , cetuximab see well work follow cetuximab two different dos intensity-modulated radiation therapy treat patient HPV-associated stage III stage IV cancer oropharynx remove surgery .</brief_summary>
	<brief_title>Induction Chemotherapy Followed By Cetuximab Radiation HPV-Associated Resectable Stage III/IV Oropharynx Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy induction therapy comprise paclitaxel , cisplatin , cetuximab follow cetuximab combination low-dose standard-dose intensity-modulated radiotherapy , measure 2-year progression-free survival ( PFS ) , patient human papillomavirus ( HPV ) -associated resectable stage III-IVB squamous cell carcinoma oropharynx . Secondary - To assess overall survival . - To evaluate objective response , local control , metastatic rate . - To evaluate early late toxicity treatment . Tertiary - To evaluate quality life speech swallow function measure Functional Assessment Cancer Therapy - General ( FACT-G ) , Functional Assessment Cancer Therapy-Head Neck ( FACT-HN ) , Vanderbilt Head Neck Symptom Survey ( VHNSS ) . - To assess effect treatment-induced fatigue general physical functioning patient head neck cancer . - To correlate functional decline clinical , physical , biologic correlative . - To evaluate radiation-resistance marker , include ERCC1 single nucleotide polymorphism protein expression , correlate treatment efficacy . - To demonstrate usefulness biomarkers , include ERCC1 , epidermal growth factor receptor ( EGFR ) , cytokine chemokine marker , plasma transform growth factor alpha ( TGFA ) transform growth factor beta ( TGFB ) level , predict progression-free survival ( PFS ) outcome parameter . - To evaluate correlation efficacy cetuximab polymorphisms FcγR-receptors . - To evaluate functional outcome biological parameter , include telomere length , angiotensin-converting enzyme polymorphism , C-reactive protein level . OUTLINE : This multicenter study . - Induction therapy : Patients receive cisplatin intravenously ( IV ) 1 hour day 1 paclitaxel IV 3 hour cetuximab IV 1-2 hour day 1 , 8 , 15 . Treatment repeat every 21 day 3 course . Patients undergo evaluation response induction therapy . Patients clinical complete response ( CR ) primary tumor site proceed group 1 concurrent radiotherapy cetuximab . Patients clinical partial response ( PR ) stable disease ( SD ) primary tumor site grossly positive disease primary tumor site proceed group 2 concurrent radiotherapy cetuximab . - Concurrent radiotherapy cetuximab : Treatment begin 14-21 day last day induction therapy . - Group 1 ( CR ) : Patients undergo low-dose intensity-modulated radiotherapy ( IMRT ) 5 day per week approximately 5 week ( 27 fraction ) . Patients also receive cetuximab IV 1-2 hour weekly 6 week . - Group 2 ( PR , SD , grossly positive disease ) : Patients undergo standard-dose IMRT 5 day per week approximately 6 week ( 33 fraction ) . Patients also receive cetuximab IV 1-2 hour weekly 7 week . Patients complete questionnaire assess fatigue , physical function , weight loss , quality life , head neck symptom burden , speech swallow function baseline 1 , 6 , 12 , 24 month completion study treatment . Tumor tissue serum sample may collect periodically correlative laboratory study . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : 83 patient</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically cytologically confirm squamous cell carcinoma oropharynx determine Hematoxylin eosin ( H &amp; E ) stain Newly diagnose disease Resectable disease OR disease expect become resectable study treatment Stage III , IVA , IVB disease determine image study ( compute tomography ( CT ) scan IV contrast magnetic resonance imaging ( MRI ) require ) complete head neck exam Paraffinembedded tumor specimen available central confirmation HPVassociated disease determine H &amp; E stain insitu hybridization ( ISH ) HPV16 immunohistochemistry ( IHC ) p16 HPVassociated disease define p16 IHCpositive and/or HPV16 ISHpositive NonHPVassociated disease define p16 IHCnegative NOTE : If limited tumor material , p16 IHC perform HPV16 ISH Measurable disease primary tumor node clinical radiographic method , define lesion ≥ 2 cm least one dimension clinical exam AND radiographic exam CT scan MRI ( lesion ≥ 1 cm least one dimension radiographic exam utilizes spiral CT scan ) No primary tumor nodal metastasis fix carotid artery , skull base , cervical spine No evidence distant metastasis Eastern Cooperative Oncology Group performance status 01 Granulocytes ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Total serum bilirubin ≤ 1.5 mg/dL Creatinine clearance ≥ 60 mL/min Negative pregnancy test Fertile patient must use effective contraception No history another malignancy ( except carcinoma situ cervix and/or nonmelanomatous skin cancer ) unless curatively treat patient diseasefree ≥ 2 year Patients follow within past 6 month eligible provide evaluated cardiologist and/or neurologist study entry : New York Heart Association ( NYHA ) class IIIIV congestive heart failure Cerebrovascular accident transient ischemic attack Unstable angina Myocardial infarction ( without ST elevation ) Prior chemotherapy Prior radiotherapy clavicle Prior surgery curative intent disease ( complete head neck exam biopsy allow ) Prior therapy specifically directly target EGFR pathway Prior severe infusion reaction monoclonal antibody Uncontrolled diabetes , uncontrolled infection despite antibiotic , uncontrolled hypertension within past 30 day Concurrent illness likely interfere study therapy prevent surgical resection Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>human papilloma virus infection</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>tongue cancer</keyword>
</DOC>